摘要
难治性白血病的治疗策略主要是加强诱导、缓解、逆转白血病细胞的多药耐药性和针对白血病细胞特定表面分子或基因的靶向治疗,文章对白血病的靶向治疗现状及研究进展进行了综述。
出处
《白血病．淋巴瘤》
CAS
2004年第6期372-375,共4页
Journal of Leukemia & Lymphoma
参考文献23
-
1Salvatore G, Beers R, Margulies I, et al.Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display [J]. Clin Cancer Res,2002,8(4): 995-1002.
-
2Bumm T, Muller C, Al-Ali H K, et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority[J]. Blood, 2003, 101(5): 1941 -1949.
-
3Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for STI571 inhibition of abelson tyrosine kinase [J]. Science, 2000,289:1938-1942.
-
4Magnusson M K, Meade K E, Nakamura R,et al. Activity of STI571 in chronic myelomonocytic leukemia with a platelet- derived growth factor beta receptor fusion oncogene[J]. Blood, 2002, 100(3):1088-1091.
-
5Golub T R, Barker G F, Lovett M. Fusion of PDGF receptor beta to a novel ets-like gene, tel in chronic myelomonocytic leukemia with t (5;12) chromosomal translocation[J]. Cell, 1994, 77:307-316.
-
6Michael C H, Charles D B, Brian J D, et al.Inhibition of Kit tyrosine kinase activity: a novel molecular approach to the treatment of Kit-positve malignancies[J]. J Clinical Oncology, 2002, 20(6): 1692-1703.
-
7Demetri G D. Targeting c-kit mutation in solid tumors: scientific rationale and novel therapeutic options [J]. Semi Oncology,2001,28(5 Suppl 17):19-26.
-
8Zhao M, Kiyoi H, Yamamoto Y, et al. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor[J]. Leukemia, 2000, 14(3):374-378.
-
9Yee K W, Keating A. Advance in targeted therapy for chronic myeloid leukemia [J].Expert Rev Anticancer Ther, 2003,3 (3):295-310.
-
10Alas S, Ng C P, Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma[J]. Clin Cancer Res, 2002, 8(3):836-845.
同被引文献8
-
1吴德沛,傅琤琤,唐晓文,孙爱宁,马骁,苗瞄,刘跃,均张日,夏学鸣.含有大剂量阿糖胞苷的联合化疗治疗难治和复发急性白血病[J].中华血液学杂志,2004,25(11):696-697. 被引量：32
-
2王荷花,冯四洲,王玫,魏嘉璘,杨栋林,闫嶂松,黄勇,刘庆国,韩明哲.成人急性淋巴细胞白血病自体造血干细胞移植后的维持治疗[J].白血病．淋巴瘤,2005,14(2):69-71. 被引量：5
-
3Coustan-Smith E,Sancho J,Hancock ML,et al.Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia[J].Blood,2000,96(8):2691～2696
-
4Buchner T,Hiddemann W,Wonnann B,et al..Acute myeloid leu-kemia in adults is postconsolidation maintenance therapy necessary[J].Int Hematol,2000,72(3):285～289
-
5Harms DO,Janka-Schaub GE.Co-operative study group for childhood acute lymphoblastic leukemia (COALL):long-term follow-up trials 82,85,89 and 92[J].Leukemia,2000,14(12):2234～2239
-
6黄绍良,方建培.异基因造血干细胞移植在治疗儿童白血病中的应用[J].中国实用儿科杂志,2002,17(6):332-335. 被引量：2
-
7汤永民.浅谈当前影响我国小儿白血病诊疗结果的几个问题[J].白血病．淋巴瘤,2002,11(5):264-266. 被引量：5
-
8谷仁凯.如何提高我国儿童急性白血病患者的长期无病生存率[J].白血病．淋巴瘤,2002,11(5):266-267. 被引量：3
二级引证文献5
-
1王君霞,葛艳丽,戴永利,罗德春,郭林梅.小儿急性淋巴细胞白血病合并水痘-带状疱疹感染的临床观察[J].中国小儿血液与肿瘤杂志,2008,13(2):79-80.
-
2王君霞,葛艳丽,戴永利.急性淋巴细胞白血病合并水痘1例[J].第四军医大学学报,2008,29(19):1787-1787.
-
3邓作勇.小儿白血病合并水痘的护理[J].当代护士（中旬刊）,2009,16(11):33-34.
-
4田荣,王春梅.1例白血病患儿化疗致Ⅳ度骨髓抑制并发带状疱疹的护理[J].护理实践与研究,2013,10(1):155-156. 被引量：1
-
5张静瑜.急性淋巴细胞白血病合并出血性水痘的诊治和护理体会[J].光明中医,2013,28(8):1712-1712. 被引量：2
-
1裴福生,李翠丽.难治性白血病的临床分析[J].白血病,1996,5(4):220-221.
-
2彭正平,钟美佐.米托蒽醌联合化疗治疗难治性白血病[J].湖南医学,1999,16(4):263-263. 被引量：1
-
3李英,徐功立.难治性白血病的治疗[J].山东医药,2000,40(6):45-45.
-
4游伟文,汪明春,蔡云,陈俊雄.以吡喃阿霉素为主化疗方案治疗难治性白血病24例分析[J].癌症,2000,19(8):831-831. 被引量：1
-
5丁凡,丁南华.复发性和难治性白血病的治疗[J].现代诊断与治疗,1995,6(2):101-103. 被引量：2
-
6熊玉宁.难治性白血病的化疗进展[J].白血病,1999,8(2):122-123. 被引量：7
-
7张天弼.联用米托蒽醌阿糖胞苷治疗难治性白血病[J].赣南医学院学报,1995,15(1):57-58.
-
8吴春华,徐秀芬.吡柔比星联合阿糖胞苷治疗难治性白血病疗效观察[J].白血病．淋巴瘤,2003,12(3):172-172. 被引量：3
-
9孙守金,高春记.去甲氧柔红霉素为主治疗难治性白血病[J].临床血液学杂志,2000,13(5):227-227. 被引量：1
-
10王少云.中大剂量阿糖胞苷治疗成人难治性白血病30例[J].中国现代医药科技,2003,3(4):15-15. 被引量：1
